Integragen (ALINT.PA) Stock Price
Integragen Price
Revenue has compounded at 4.3% per year over the past 18 years to 5.02 M EUR. Integragen's net margin stands at -53.1%, down from 0.1% several years earlier.
Integragen stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Integragen business model & stock analysis
Frequently asked questions about Integragen
Integragen SA is a leading company specializing in innovative genomic services and molecular diagnostics. Their business model revolves around providing personalized healthcare solutions through cutting-edge genetic analysis and bioinformatics. By leveraging their expertise in advanced sequencing technologies, Integragen offers accurate and reliable genetic testing services to improve patient care. They prioritize collaboration with healthcare professionals and researchers to deliver customized genomic insights for a range of applications, including cancer diagnostics, rare diseases, and pharmacogenomics. Integragen SA's commitment to leveraging genomics for better health outcomes makes them an esteemed player in the field of precision medicine.
Integragen SA is primarily active in the field of genetic sequencing and molecular diagnostics for cancer and autism. This French biotechnology company specializes in providing innovative solutions and services to healthcare professionals and researchers. With its cutting-edge technology and expertise in genomics, Integragen SA aims to improve patient care and advance scientific discoveries in these critical areas.
The main competitors of Integragen SA in the market include Genomic Health Inc., Foundation Medicine Inc., and Veracyte Inc.
Integragen SA, founded in 2000, is a leading biotechnology company specializing in genomic solutions for personalized medicine. Headquartered in France, the company focuses on the development and implementation of advanced genomic testing methods. With a strong background in genetic research, Integragen SA offers comprehensive molecular diagnostics and innovative solutions for disease management. Its expertise lies in genetic sequencing, bioinformatics, and data analysis, enabling it to provide personalized insights into various medical conditions. Integragen SA's commitment to revolutionizing healthcare through genomics has established it as a trusted partner in the advancement of personalized medicine.
Integragen SA, a leading company in the field of genomics, has achieved numerous significant milestones. One notable achievement is their development of innovative genomic solutions, catering to the needs of both academic researchers and healthcare professionals. By leveraging their advanced technology and expertise, Integragen SA has successfully provided high-quality genomic sequencing and analysis services to various institutions and organizations. Additionally, the company has made significant contributions to the development of personalized medicine, allowing for better understanding and treatment of complex diseases. Integragen SA's commitment to excellence and continual innovation has positioned them as a prominent player in the genomics industry, driving advancements in healthcare and research.
Integragen SA is primarily present in France, the United States, and Belgium.
Integragen SA represents strong values and a unique corporate philosophy. With a focus on innovation and scientific excellence, Integragen SA constantly strives to provide cutting-edge genetic solutions to its clients. The company's commitment to quality and precision enables them to offer personalized healthcare and diagnostic services, catering to the individual needs of each patient. Integragen SA prioritizes ethical practices and values collaboration, fostering partnerships with leading research institutions and healthcare providers. By harnessing the power of genomics, Integragen SA aims to improve patient outcomes and contribute to the advancement of precision medicine.
9 analysts currently rate the Integragen stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Integragen to generate revenue of 6.50 M EUR and earnings per share of -0.21 EUR.
The Integragen share (ALINT.PA) is listed on 2 stock exchanges, including: Paris (ALINT.PA).
Integragen SA is a company specialized in the development and sale of genetic tests and data analysis. The company was founded in 2000 and is headquartered in Evry, France. Its core business is DNA sequencing and analysis, conducting genome studies, pharmacogenomics, biomarker development, precise diagnostics, and personalized medicine. Integragen has three core divisions: Biopharmaceuticals, Medical Genomics, and Research Support. It offers services to support biotech and pharmaceutical companies in developing personalized medicines, assists healthcare professionals in identifying genetic changes in patients, and provides comprehensive genomics services for genetic research. The company also offers various genetic tests for cancer prevention and diagnosis, assessing the risk of cardiovascular diseases, and grouping metabolism processes. Integragen has a wide network of partners in the biotech and pharmaceutical industry, as well as academia, and aims to expand its business through strategic partnerships and acquisitions. In summary, Integragen is a leading company in the genomics industry with a wide range of services and products, focusing on personalized medicine and genetic research to drive growth in the coming years.
The expected revenue of Integragen is 6.50 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Integragen is -1.48 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Integragen is currently -0.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Integragen stock.
The price-to-sales ratio (P/S) of Integragen is currently 0.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Integragen stock.
The Eulerpool Quality Score for Integragen is 4/10.
The ISIN of Integragen is FR0010908723. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Integragen is A1J1JV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Integragen is ALINT.PA. The ticker symbol is used to trade Integragen shares on the stock exchange.
Integragen stock
Integragen Peer Group
Integragen Ticker
Integragen FIGI
All fundamentals and in-depth analysis of Integragen
Our stock analysis for Integragen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integragen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.